TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05151744
Drug: Vamikibart
Normalized name: Vamikibart
DrugBank: Vamikibart (DB18896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamikibart will be administered by IVT injection in the study eye.
Study: NCT00002337
Drug: Vesnarinone
Normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05717153
Drug: Eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05090592
Drug: 0.01 atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% atropine eye drop prevent myopic progression
Study: NCT05151744
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab will be administered by IVT injection in the study eye.
Study: NCT05717153
Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate
Normalized name: neopentyl glycol dicaprate
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05142904
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I-131 according to standardized doses-calculation.
Study: NCT05142904
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I-131 according to local standard.
Study: NCT05832073
Drug: Natural full human monoclonal antibody CBB 1 injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Study: NCT05832073
Drug: Rabies Human Immunoglobulin (HRIG)
Normalized name: Rabies immunoglobulin (human)
DrugBank: Rabies immune globulin, human (DB11603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: Rabid human immunoglobulin
Study: NCT05832073
Drug: Natural full human monoclonal antibody CBB 1 injection placebo
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
Study: NCT05975684
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
Study: NCT06104826
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emicizumab in Hemophilia A
Study: NCT05690802
Drug: Palonosetron hydrochloride capsules
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.
Study: NCT05039086
Drug: PDE5 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
Study: NCT05039086
Drug: Endothelin Receptor Antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
Study: NCT05279677
Drug: Fecal microbiota transplantation plus Sintilimab and Fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w.
Study: NCT05237843
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
Study: NCT02633514
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2,iv gtt,d1-3
Study: NCT02633514
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75mg/m2,iv gtt,d1-3
Study: NCT00021554
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05614544
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for induction of general anesthesia
Study: NCT05570669
Drug: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose
Normalized name: Rho(D) immune globulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking the colonoscopy preparation drug (Clensia) in a single administration
Study: NCT05006638
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a drug used as an antidote for some types of pesticides
Study: NCT05006638
Drug: Sodium Bicarbonate Powder and ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
Study: NCT05141422
Drug: SHR2150 tablet、efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SHR2150 tablet single dose, Efavirenz single dose.
Study: NCT04523363
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dosage of 500 mg tablets 2 times a day (with each meal)
Study: NCT01634399
Drug: Torrent's Quetiapine Fumarate Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05679193
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily
Study: NCT05549804
Drug: KL340399 Intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
Study: NCT05028569
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injection
Study: NCT06336603
Drug: Winlevi (clascoterone) 1% & Adapalene 0.3% gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
Study: NCT05320926
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
Study: NCT00002150
Drug: Celgosivir hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Celgosivir (DB06580)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04515602
Drug: PARPi
Normalized name: PARPi-FL
DrugBank: PARPI F-18 (DB18657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
Study: NCT06781281
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab
Study: NCT06326060
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide will be administered subcutaneously.
Study: NCT05747157
Drug: Metabolically Armed CD19 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
Study: NCT04673643
Drug: Hyaluronic acid eye drops
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study: NCT05174416
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mavacamten Capsules
Study: NCT05562518
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
Study: NCT05562518
Drug: dehydroepiandrosterone
Normalized name: Dehydroepiandrosterone
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal ovule daily
Study: NCT05684172
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
Study: NCT05348213
Drug: Zanubrutinib plus R-ICE
Normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT05348213
Drug: Decitabine plus R-ICE
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT05348213
Drug: Tofacitinib plus R-ICE
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT05348213
Drug: Pomalidomide plus R-ICE
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT05562518
Drug: Estrogen + probiotics
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal ovule daily for 12 consecutive days, followed by 1 vaginal ovule 2 times per week
Study: NCT05562518
Drug: Moisturizer
Normalized name: MOISTURIZER
DrugBank: Oxybenzone (DB01428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal ovule daily for 14 consecutive days, followed by 1 vaginal ovule every three days
Study: NCT06451406
Drug: Selective serotonin re-uptake inhibitor
Normalized name: Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received selective serotonin re-uptake inhibitor as medical treatment for treatment of premature ejaculate.
Study: NCT06451406
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received injection of glans penis with hyaluronic acid
Study: NCT06651905
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
Study: NCT06651905
Drug: Superior laryngeal nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
Study: NCT06655012
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
Study: NCT06654687
Drug: Ringer lactate 1000 ml
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.
Study: NCT06654687
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 250 mL of human albumin 5% over 10 minutes
Study: NCT06654687
Drug: Ringer lactate 750 ml
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.
Study: NCT05129358
Drug: Dehydration
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
Study: NCT06593782
Drug: Dolasetron
Normalized name: Dolasetron
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Study: NCT06593548
Drug: Ivosidenib (AK112)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
Study: NCT05801679
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
Study: NCT06602622
Drug: Integrase inhibitor
Normalized name: Integrase inhibitors
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
Study: NCT06602622
Drug: Doravirine + tenofovir DF + lamivudine
Normalized name: doravirine / lamivudine / tenofovir disoproxil
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
Study: NCT06586177
Drug: Anti-CD20 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
Study: NCT06285019
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, ivgtt, d1, 21 days for a cycle
Study: NCT06782334
Drug: AMT-116
Normalized name: Amtagvi
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT-116 is an antibody Drug Conjugate (ADC)
Study: NCT04774094
Drug: Zavicefta, Ceftazidime-Avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
Study: NCT06285019
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg, ivgtt, d1, 21 days for a cycle
Study: NCT05776407
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is used for lymphodepletion.
Study: NCT05776407
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide is used for lymphodepletion.
Study: NCT05324059
Drug: Pregabalin 75mg/ Tramadol 50 mg
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
Study: NCT05324059
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
Study: NCT06421532
Drug: XYWAV
Normalized name: Xywav
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily before bedtime for 3 months
Study: NCT06519708
Drug: Erector Spinae Plane Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
Study: NCT06519708
Drug: External Oblique Intercostal Plane Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
Study: NCT04833777
Drug: Local Anesthetics Lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
Study: NCT04833777
Drug: Local Anesthetics Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
Study: NCT05217693
Drug: BB-1705
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
Study: NCT05586438
Drug: Colistin Sulfomethate
Normalized name: Colistin sulfomethate
DrugBank: Colistimethate (DB01111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
Study: NCT05855811
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab should initiated within 6 months after the end of treatment for FPC.
Study: NCT06145945
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml saline is sprayed intraperitoneally
Study: NCT05406466
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PD-1 immune check inhibitor
Study: NCT04727307
Drug: Atezolizumab (neoadjuvant)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
Study: NCT04727307
Drug: Bevacizumab (adjuvant)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
Study: NCT04727307
Drug: Atezolizumab (adjuvant)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
Study: NCT05406466
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: multitargeted receptor tyrosine kinase inhibitor
Study: NCT05876182
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.